Edesa Biotech to Join Panel Discussion at Industry Event
Edesa Biotech (NASDAQ:EDSA) announced that CEO Dr. Par Nijhawan will participate in a virtual panel hosted by the Ontario Bioscience Innovation Organization on June 1, 2021, at 12:00 PM ET. The discussion will center on the topic "Health Science IPOs: Will We Continue To Break Records?" Edesa is a biopharmaceutical company focused on developing therapies for inflammatory diseases, with two lead candidates: EB05 for Acute Respiratory Distress Syndrome and EB01 for chronic allergic contact dermatitis.
- Dr. Par Nijhawan's participation in a notable industry panel could enhance Edesa's visibility among investors.
- Edesa is advancing two product candidates, EB05 and EB01, in late-stage clinical studies addressing significant medical needs.
- No specific financial updates or clinical trial data were disclosed, which may leave investors with uncertainty regarding progress.
TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by the Ontario Bioscience Innovation Organization. As part of a panel of health science and investment professionals, Dr. Nijhawan is expected to discuss publicly available information regarding Edesa and its corporate strategy.
The panel discussion, which is titled "Health Science IPOs: Will We Continue To Break Records?" is scheduled to take place on Tuesday, June 1, 2021 at 12:00 PM Eastern Time. More information is available at the event website.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. By targeting sPLA2 with enzyme inhibitors - at the inception of inflammation rather than after inflammation has occurred - Edesa believes that drugs based on this technology could provide a powerful anti-inflammatory therapeutic strategy for treating diverse inflammatory/allergic conditions. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact:
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com
SOURCE: Edesa Biotech
View source version on accesswire.com:
https://www.accesswire.com/649442/Edesa-Biotech-to-Join-Panel-Discussion-at-Industry-Event
FAQ
What is the purpose of Edesa Biotech's participation in the event on June 1, 2021?
What are Edesa Biotech's lead product candidates?
Where is Edesa Biotech located?
What type of company is Edesa Biotech?
What are the potential risks mentioned in Edesa Biotech's forward-looking statements?
